Yes, its in the last 10Q, note #9 on page 16, under related party transactions. It does appear to be convoluted, but the question is whether there is anything not kosher? Or anything directly in conflict with the clinical trials proposed or underway?

Ehrlich knows he needs an independent BoD to uplist. The sooner he garners independent oversight, the more confidence he will instill in shareholders and institutions going forward.